ELYM | Eliem Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.03 - 8.79
52 Week Range	2.3500 - 11.55
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	242,710
Average Volume	255,127
Shares Outstanding	67,060,199
Market Cap	552,576,040
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-08-10

Valuation
Profitability
Growth
Health
P/E Ratio	-3.71
Forward P/E Ratio	N/A
EPS	-2.22
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	USA
Website	ELYM

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

ELYM's peers: ACIU, ADAG, ANTX, ARTL, ATAI, NTRB, PMCB, CCCC, CDXC, CLGN, CLLS, CLNN, CRMD, CSBR, CUE, CYCC, DBVT, DYAI, PMVP, MNOV, PHVS, PEPG, ANEB, RZLT, HCWB, MOLN, AVTE, ACRV, CYT, PRDS, STTK, IPSC, ETON, EWTX, FENC, GANX, GHRS, GNFT, GNTA, HOWL, ICCC, IKNA, INBX, INMB, CYBN, IOBT, IPA, IPHA, IVA, JANX, DRTS, JSPR, KTTA, KYMR, LUMO, LVTX, MDWD, MNMD, MRNS, MTNB, NAUT, NLSP, NRIX, NVCT, OMGA, OPT, ORGS, PCSA, PHAR, PRAX, PRLD, PRTC, PRTG, RAPT, RLMD, RLYB, SEEL, SLGL, SLN, STRO, THTX, TRDA, TSHA, URGN, VALN, XCUR, XLO, XOMA, HLVX, PLUR, THRD, VANI, NAMS, LIPO, COYA, ELVN, GRI, CVKD

*Chart delayed

Analyzing fundamentals for ELYM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see ELYM Fundamentals page.

Watching at ELYM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ELYM Technicals page.